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Introduction
The concept of the intraductal approach to evaluating the
breast microenvironment assumes direct access to the
breast cancer containing duct. Previous studies on duct
anatomy infusing a dye or contrast found fluid-yielding
ducts to be associated with the cancer containing duct in
approximately 50% of fluid-yielding breasts with cancer.
A concordant anatomical relationship between accessible
ductal sytems and the cancer-affected lobe is essential if
cytology or other cell markers are to be successfully iden-
tified as indicators of cancer or of early cancerous change.
The concordant relationship is less important if field
change effects are considered to predictors of malignant
change. The aim of this study was to determine how often
duct lavage effluent drains the breast cancer affected seg-
ment.
Methods
40 patients undergoing therapeutic mastectomy for breast
cancer were studied (31 symptomatic and 9 screen-
detected). Following successful ductal lavage, the mastec-
tomy specimens were infused ex-vivo with coloured poly-
urethane elastomer resin (VasQtec, Zurich). The extent of
specimen infusion with resin and the direct anatomical
relationship to the cancer affected segment were recorded.
Results
The median number of successful ducts cannulated per
cancer affected breast was 2 (range 1–3). 23/40 (58%)
therapeutic mastectomy specimens showed successful
tracing of the cancer-affected duct system. 5/38 (13%)
resin infusions traced duct systems unaffected by cancer
and the remaining 12/40 (30%) infusions extravasated.
Of the 23 successful tracings, 16 mastectomy specimens
contained symptomatic cancer and the remaining 7 were
screen-detected nonpalpable cancers. All 12 extravasated
infusions occurred in specimens with symptomatic can-
cer. 7/23 successful infusions showed abnormal cytology
concordant with the cancer affected segment.
Conclusion
Breast duct systems of both symptomatic and non-palpa-
ble cancer were equally accessed at successful ductal lav-
age. The duct system of the cancer affected segment was
concordant to a fluid yielding duct patent in 58 percent of
cases, a similar finding to previous studies. Mastectomy
specimens containing clinically impalpable disease were
more likely to remain patent than those with palpable
lesions, implying distal duct collapse following duct
obstruction by larger tumours impedes access to the can-
cer affected lobe. Future studies that depend on direct
access to the cancer affected segment (eg cytology) are
likely to be limited by duct accessibility while studies that
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demonstrate field change effects (eg protein studies) are
less dependent on duct patency.